The Revolutionizing Role of Clay Siegall in Cancer Research

The cancer research and treatment organization, Seattle Genetics, has moved to new heights since its establishment in 1997. As the Co-founder, CEO, Boards’ chairperson, and President of the company, Dr. Clay Siegall has actively demonstrated his passionate quest of improving lives and eradicating pain for cancer patients. He systematically rose in his profession where he began as a senior research investigator at the Myers Squibb Institute.

His promotion to work as a Staff Fellow and Biotechnology Fellow at the National Cancer Institute followed closely, enabling him to continue collaborating with various stakeholders in advancing the cancer research he had initiated. Through him, Seattle Genetics received a financial invasion of more than 1.2 billion dollars from the private funding, which supported the company’s mission of promoting innovative technological treatments for cancer worldwide.

As the leader of Seattle Genetics, Siegall has a core responsibility of raising funds needed in the extensive researches and endeavors in managing cancer. In addition, his leadership acumen is of importance not only to his co-founded firm but also to the cancer research community. He spearheads the production of medicine and provides information on conducting productive research that aid in the vision and mission of the community. Through the numerous articles he has published, he educates people on new research methodologies. He understands the importance of human capital in cancer management hence his approval of hiring more workers.

His role revolves around revolutionizing cancer management through research and drug development. Setting the bar reasonably high, Siegall silently leads his company and other competitors in working hard to move to great heights as far as the cancer treatment is concerned. With his dedication, he is very promising to the world to release a variety of new and reliable medications to fight cancer.

Dr. Siegall’s contributions for the cancer research communities and private organizations are significant. In 2012, he was recognized as the alumnus of the year at the University of Maryland. His enthusiasm in supporting cancer patients remains unquenched. The production and approval by FDA of the ADCETRIS, an antibiotic conjugate for cancer, was just but his first success.

Together with his team at Seattle Genetics, he is planning to produce twelve drugs that will continually help affected populace in more than 60 countries.